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Abstract
In this study, 1R,2R-dicamphanoyl-3,3-dimethydihydropyrano[2,3-c]xanthen-7(1H)-one (DCX)
derivatives were designed and synthesized as novel anti-HIV agents against both wild-type and
nonnucleoside reverse transcriptase (RT) inhibitor-resistant HIV-1 (RTMDR-1) strains. Twenty-
four DCX analogs (6-29) were synthesized and evaluated against the non-drug-resistant HIV-1
NL4-3 strain, and selected analogs were also screened for their ability to inhibit the RTMDR-1
strain. Compared with the control 2-ethyl-3′,4′-di-O-(-)-camphanoyl-2′,2′-
dimethyldihydropyrano[2,3-f]chromone (2-EDCP, 2), one of the best anti-HIV coumarin
derivatives in our prior study, three DCX compounds (7, 12, and 22) showed better activity
against both HIV strains with an EC50 range of 0.062 – 0.081 μM, and five additional compounds
(8, 11, 16, 18, and 21) exhibited comparable anti-HIV potency. Six DCX analogs (7, 11-12, 18,
and 21-22) also showed enhanced selectivity index (SI) values in comparison to the control.
Structure-activity relationship (SAR) information suggested that the extended conjugated system
of the pyranoxanthone skeleton facilitates the interaction of the small DCX molecule within the
viral binding pocket, consequently leading to enhanced anti-HIV activity and selectivity.
Compared to DCP compounds, DCX analogs are a more promising new class of anti-HIV agents.
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AIDS has been epidemic for over 30 years, but still no cure has been identified. Although
over 30 formulations are now approved by the US FDA to treat AIDS, drug resistance
problems have dramatically reduced the efficacy of current anti-HIV agents. Therefore,
research to find new anti-HIV agents with either higher potency or novel mechanism has
attracted great attention to overcome this problem.
In our prior studies, 3'R,4'R-di-O-(-)-camphanoyl-(+)-cis-khellactones (DCKs) and their
positional isomers, 4H-chrom-4-one derivatives (DCPs), showed high potency against wild-
type HIV-1 replication (Fig. 1). DCP analogs also showed promising anti-HIV potency
against drug-resistant HIV strains. Among previously reported DCP analogs, 2-ethyl DCP
(2-EDCP, 2) and 2,5-dimethyl DCP (3) exhibited the best anti-HIV activity against both
wild-type and drug-resistant strains with remarkable EC50 values of 0.07 and 0.11 μM for 2
and 0.036 and 0.49 μM for 3 (Fig. 1) [1, 2]. More specifically, preliminary mechanism of
action-related studies indicated that a DCK analog (4-methyl DCK, 5) inhibited the activity
of HIV-RT through inhibition of DNA-dependent DNA polymerase activity [3], in contrast
to currently available non-nucleoside reverse transcriptase inhibitors (NNRTIs) that block
HIVRT by inhibiting RNA-dependent DNA polymerization [4, 5]. The mechanistic and
structural uniqueness of DCK and DCP analogs opened a new avenue for us to discover
more potent, more effective novel anti-HIV drugs for AIDS therapy.
As previously described, structure-activity relationship (SAR) study and pharmacophore
analysis based on DCP suggested that the planar ring system is an important pharmacophore
to maintain anti-HIV activity against both wild-type and multi-drug resistant HIV strains [6].
We speculated that adding an aromatic ring onto the 4-pyrone ring of DCPs could produce a
more rigid planar system, and that the extended conjugation might sustain or even increase
the π-π stacking interaction between the ligand and the target protein.
Therefore, in order to further understand the interaction between the compounds’ planar ring
and the binding pocket, we designed a series of tri-aryl conjugated compounds, with a
xanthen-9-one moiety replacing the chromone ring in the DCP series (Fig. 2). We postulated
that this modification could enhance the interaction between the drug molecules and the
target proteins, and therefore, improve the anti-HIV activity and selectivity profiles.
2. Design
In previous studies, introducing appropriate alkyl or O-alkyl groups on the planar ring
system dramatically improved the anti-HIV activity. For example, 2-EDCP (2) and 4-methyl
DCK (5) exhibited four- and five-fold better anti-HIV activity than the parent DCP (1) and
DCK (4), respectively. Thus, in our current study, we first designed DCX analogs with a
series of small alkyl and O-alkyl groups substituted on the C ring (R8 – R11) and A ring (R6)
to evaluate the effects of alkyl substitutions (Fig. 2, compounds 6, 7, and 10-18). We then
introduced other functional moieties, such as halogen, cyano, and hydroxy groups, with
different physicochemical properties, as well as prepared a DCX oxime analog, to explore
how these functionalities affect the anti-HIV activity (EC50) and selectivity index (SI, CC50
÷ EC50) (Fig. 2, compounds 8, 9, and 19-29). In addition to its inductive electron
withdrawing effect, a cyano group could further expand the conjugation of the xanthenone
ring, and perhaps result in potent anti-HIV activity. A hydroxy group could not only
increase polarity, but also could be derivatized to obtain water soluble salts.
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The general synthetic route to obtain pyrano-xanthones is shown in Scheme 1. Hydroxylated
xanthones (32b-i, 32k-q) were produced through a cyclization reaction between
phloroglucinol (30) and appropriate substituted salicylic acids (31b-j, 31l-q), in the presence
of Eaton's reagent (phosphorus pentoxide solution in methanesulfonic acid) as a catalytic
condensation agent [7]. A slight excess of phloroglucinol was used to complete the desired
reaction and avoid the formation of side products (hydroxychromeno[3,2-b]xanthenediones).
The desired products (32b-i, 32k-q) were obtained as brown solids after precipitation in ice-
water, and were collected by filtration. They were used in the next reaction step without
further purification. 6-Hydroxy-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-ones (33b-i, 33k-
q and 34a) were synthesized from the xanthones (32, 32a is commercially available) in
anhydrous pyridine by microwave-assisted alkylation and cyclization at 220 °C for 4 h [8].
Methylation of the resulting 6-hydroxy-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-ones (33)
with methyl iodide and potassium carbonate yielded 6-methoxy-3,3-
dimethylpyranoxanthones (34b-q) [9].
DCX analogs 6, 7, and 10-24 were synthesized from 34 by following the established
literature procedures [5] for Sharpless asymmetric dihydroxylation [10. 11], which gave
intermediate diols (35), followed by esterification [11, 12] with excess (S)-camphanoyl
chloride (Scheme 2).
Reaction of 7 with NH2OH·HCl in anhydrous pyridine afforded DCX oxime analog 8.
Demethylation of 7 with 48% hydrobromic acid solution yielded 6-hydroxy-DCX (9) in
63% yield [9]. (Scheme 3)
Brominated DCXs (25-27) were synthesized by reaction of 7 and 12 with N-
bromosuccinimide (NBS) under appropriate conditions. Bromination of 7 and 12 at the 5-
position was accomplished in dichloromethane under microwave conditions to generate 25
and 26, respectively [13], while benzylic bromination of 12 with NBS in anhydrous carbon
tetrachloride in the presence of m-chloroperoxybenzoic acid (mCPBA) as a radical initiator
led to 27 (Scheme 4) [6].
Scheme 5 illustrates the synthetic pathway to 6-methoxy-10-cyano-DCX (28) and 6-
methoxy-9-cyano-DCX (29). Compounds 34o and 34p were treated with zinc cyanide in the
presence of tetrakis(triphenylphosphine)palladium(0) [Pd(PPh3)4] as a catalyst to afford 36
and 37 [14]. After dihydroxylation and esterification following the existing procedures
mentioned above [6-8], compounds 28 and 29 were obtained.
4. Results and discussion
All synthesized DCX analogs were screened against the wild-type HIV-1 NL4-3 strain in a
single cycle infection assay using TZM-bl cells. The results are shown in Table 1.
The structures of 6, 7, and 9 differ only by the substituent at C-6; however, this slight
structural differentiation resulted in significant deviation in anti-HIV activity. Analog 7,
with a methoxy group at C-6, had an EC50 value of 0.063 μM, and was five-fold more potent
than the unsubstituted 6. Analog 7 was also 1.5-fold more potent than 2, the positive control,
and had a two-fold higher SI value, suggesting a better selectivity between HIV inhibition
and cytotoxic activity. In contrast, compound 9, a6-hydroxy DCX analog, did not show
notable activity or selectivity (an average SI value less than 4 was observed). One possible
explanation for the lack of anti-HIV potency is that intramolecular H-bonding (HB) between
the OH at C-6 and the carbonyl oxygen at C-7 might disrupt HB interaction between this
oxygen and the target protein. However, 19, with a hydroxy group at C-8 rather than C-6,
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exhibited some anti-HIV activity (EC50 0.33 μM) and selectivity (SI 24.5), indicative of
unequal HB effects between the carbonyl oxygen and the two similar adjacent OH groups
(6-OH versus 8-OH). An unequal molecular environment or point-by-point interactions of
the substituents on the drug molecule with the target protein could, in turn, weaken the
intramolecular interaction of the 8-OH. Overall, the data suggested that introducing a
hydrophobic, rather than hydrophilic, substituent at C-6 is a good strategy to maintain or
enhance anti-HIV activity and selectivity, and consequently, all other target compounds
have a 6-OMe group.
The DCX oxime analog, 8, exhibited somewhat decreased anti-HIV activity against wild-
type HIV strain in comparison with its oxo counterpart 7, indicating that the carbonyl group
at C-7 likely interacts with the binding pocket as a HB acceptor, while the NOH group in the
oxime analog attenuates such interaction.
Compounds 7, 10, 14, and 20 have different substituents at C-11 (R11). The unsubstituted 7
(R11 = H) exhibited higher potency than 20 (R11 = F), which was more potent than 10 (R11
= CH3) (EC50 0.063, 0.23 and 1.52 μM, respectively). 11-Methoxy-DCX (14) showed no
detectable anti-HIV activity or selectivity against wild-type HIV-1 NL4-3 strain. The R11
substituent may influence the orientation of the 1-camphanoyl group, as was previously
shown to be significant to maintain high anti-HIV potency in the DCP series [2]. Introducing
R11 substitutions also led to increased cytotoxic activity (smaller CC50 value was observed),
which consequently led to lower SI values.
In our previous study, the 2- and 3-positions of the chromone system in DCP analogs,
displayed equivalent characteristics when substituted with the same functionalities [6].
Therefore, in this study, we compared the introduction of methyl and methoxy substituents
at the 9- or 10-position of DCX compounds (analogs to the 2- and 3-position, respectively,
in DCP compounds). 9- (12) and 10-Methyl- (11) DCX analogs showed similar EC50 values
(0.065 vs 0.095 μM, respectively), with 12 being slightly more potent than 11, while 9-
methoxy-DCX (16) was three-fold more potent than 10-methoxy-DCX (15) (EC50 0.12 and
0.362 μM, respectively). Relative to 7, methylation at C-9- or C-10 did not affect anti-HIV
potency, but methoxylation at these positions decreased the potency.
The effect of substitution at C-8 on anti-HIV activity was also studied, and the rank order of
potency was 8-F (22) > 8-CH3 (13) > 8-OH (19) > 8-OCH3 (17). 8-Fluoro-substiuted DCX
(22) exhibited the greatest anti-HIV activity and selectivity, with an EC50 value of 0.062 μM
and SI value greater than 224,which were equivalent to the values for 7. Thus, the F atom
with a similar size to H led to similar activity. None or a small substituent, such as H or F, is
required at C-8 to maintain or enhance anti-HIV activity. Similarly, 9-fluoro-DCX (21) also
showed good anti-HIV potency and selectivity.
However, bromination of the A- or C-ring in DCX led to reduced anti-HIV activity. Except
for 10-Br-DCX (24), which exhibited only weak anti-HIV efficacy (EC50 1.47 μM), all other
compounds (23, 25-27) lacked significant anti-HIV potency.
Introducing a cyano group at C-10 or C-9 resulted in compounds 28 and 29, respectively.
Both compounds exhibited considerable anti-HIV activity, with EC50 values of 0.20 and
0.29 μM.
Eight new DCX analogs, which showed significant anti-HIV activity against the wild-type
HIV strain, were selected and screened against the drug-resistant RTMDR1 HIV strain. The
data are listed in Table 2. Interestingly, all selected DCX analogs (6, 7, 11-13, 16, 21, 22)
also showed activity against the drug-resistant strain. Based on both EC50 and SI values,
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compound 22 was the most active compound followed by 7, 12, and 21. The activity profile
from the drug-resistant HIV strain was consistent with that from the wild-type HIV strain.
In conclusion, the bioassay data generated from this study demonstrated that the new DCX
compounds are potent and promising anti-HIV agents, with some analogs being more active
than the lead DCP compound 2. The following SAR conclusions were derived from this
study.
1. The planar ring extension from a two-ring conjoined system (pyranochromone in
DCP) to a three-ring conjoined system (pyranoxanthone in DCX) retained or even
increased the anti-HIV activity against both wild-type and drug-resistant strains,
suggesting that a conjugated planar ring system may be essential to interact with
the target protein through a π-π ring stacking interaction. The larger DCX molecule
with enlarged conjugating planer system perhaps, would interact more efficiently
with viral amino acid residues.
2. Compared to DCPs, selected DCXs, such as 7 and 22, exhibited increased
selectivity (SI values), suggesting DCX analogs target the virus-infected cells
efficiently and are less cytotoxic to normal cells.
3. The positioning of the substituents in the molecule dramatically affected the anti-
HIV activity against both viral strains. Adding a methyl group at C-11 generated an
almost inactive compound (10), while adding the same group at C-9 or C-10 led to
two potent anti-HIV compounds (12 and 11, respectively). A methoxy group was
essential at C-6 for enhanced anti-HIV potency, and a second methoxy group was
more efficacious at C-9 (16) than at C-10 (15), C-8 (17), or C-11 (14). Although
the 6-hydroxy-DCX analog (9) did not exhibit anti-HIV activity, the 6-methoxy-8-
hydroxy-DCX compound (19) was relatively active with an EC50 value of 0.3 μM.
4. The properties of the substitutions at the positions also played an important role. As
mentioned above, a free OH group at C-6 resulted in an inactive compound (9),
while changing the OH to OCH3 at this position led to one of the most active
compounds (7). Generally, methyl substituted compounds showed more potent
anti-HIV activity than the corresponding methoxy substituted compounds. A cyano
group at C-9 or C-10 was well tolerated. An oxime at C-7 lowered the anti-HIV
activity, likely by reducing the HB accepting capacity relative to a 7-carbonyl
group.
5. Conclusion
Our study indentified a new entity, DCX, and a series of DCX analogs, as potent anti-HIV
agents. Most of the synthesized DCX analogs were active against both wild-type and drug-
resistant HIV strains. Compared to the control 2-EDCP (2), three compounds (7, 12, and 22)
showed better activity against both HIV strains, and another five compounds (8, 11, 16, 18,
and 21) exhibited comparable anti-HIV potency against the wild-type HIV strain. The
compounds that exhibited high anti-HIV potency also had high SI values. Six analogs (7, 11,
12, 18, 21, 22) showed enhanced SI values in comparison to the control. We also established
an anti-HIV SAR study based on both wild-type and drug-resistant HIV strains. Further
modification is currently ongoing to further improve the anti-HIV potency and
pharmacological profile of this compound type.
Zhou et al. Page 5















The proton nuclear magnetic resonance (1H NMR) spectra were measured on Varian Inova
400 MHz and 300 MHz Varian Gemini 2000 spectrometers using TMS as internal standard.
The carbon nuclear magnetic resonance (13C NMR) spectra were measured on Varian Inova
400 MHz Varian Gemini 2000 spectrometer using TMS as internal standard. The solvent
used was CDCl3 unless indicated. Microwave reactions were performed with a Biotage
initiator EXP US. Mass spectra were measured on Shimadzu LCMS-2010 (ESI-MS).
Biotage Flash and Isco Companion systems were used for medium-pressure column
chromatography. Commercial chemicals were obtained from Aldrich.
6.1.1. Synthesis of substituted 1,3-dihydroxy-9H-xanthen-9-ones (32)—To a
mixture of commercially available phloroglucinol (1.2 equiv) and an appropriate substituted
salicylic acid (1 equiv), 20 mL of Eaton's reagent (P2O5-CH3SO3H) was added slowly. The
mixture was stirred for 3 h at 80 °C, cooled to rt, and poured onto ice. After vigorous stirring
at rt for 2 h, a brown solid was precipitated. The solid was collected by filtration, washed
with water (pH ~ 6), and dried at 60 °C. In most instances, this intermediate 1,3-
dihydroxy-9H-xanthen-9-one was used without further purification.
6.1.1.1. 1,3-Dihydroxy-9H-xanthen-9-one (32b): 1H NMR δ 8.15 (1H, d, J = 8.1 Hz, H-8),
7.85 (1H, t, J = 8.1, 6.9 Hz, H-6), 7.61 (1H, d, J = 8.1 Hz, H-5), 7.49 (1H, t, J = 8.1, 6.9 Hz,
H-7), 6.41 (1H, s, H-4), 6.23 (1H, s, H-2).
6.1.1.2. 1,3-Dihydroxy-7-methyl-9H-xanthen-9-one (32e): 1H NMR δ 12.88 (1H, s,
OH-1), 11.03 (1H, s, OH-3), 7.92 (1H, s, H-8), 7.68 (1H, d, J = 8.4 Hz, H-5), 7.52 (1H, d, J
= 8.4 Hz, H-6), 6.41 (1H, s, H-4), 6.22 (1H, s, H-2), 2.44 (3H, s, CH3-7).
6.1.1.3. 1,3,8-Trihydroxy-9H-xanthen-9-one (32k): 1H NMR δ 11.86 (1H, s, OH-1), 11.80
(1H, s, OH-8), 7.68 (1H, t, J = 8.4, 8.4 Hz, H-6), 7.01 (1H, d, J = 8.4 Hz, H-5), 6.80 (1H, d,
J = 8.4 Hz, H-7), 6.39 (1H, d, J = 2.1 Hz, H-4), 6.23 (1H, d, J = 2.1 Hz, H-2).
6.1.2. Synthesis of 6-hydroxy-3,3-dimethylpyrano[2,3-c]-7(3H)-ones (33)—A
mixture of starting compound (32c-i, 32k-q) (1 equiv), 4,4-dimethoxy-2-methyl-2-butanol
(1.5-2 equiv) and anhydrous pyridine (2-3 mL) was heated at 220 °C for 4 h under high-
absorption microwave conditions. The reaction mixture was cooled to rt, diluted with
EtOAc, and washed with aqueous HCl (10%), and brine. The organic layer was separated,
and solvent was removed in vacuo. Crude products33b, 33d and 33e were used without
further purification in the methoxylation reaction, while the remaining compounds were
purified by column chromatography with hexane:EtOAc = 97:3.
6.1.2.1. 6-Hydroxy-3,3,11-trimethylpyrano[2,3-c]xanthen-7(3H)-one (33c): 43.6% yield
(starting from 1.0 g of crude 32c); 1H NMR δ 13.22 (1H, s, OH-6), 8.09 (1H, d, J = 7.6 Hz,
H-8), 7.54 (1H, d, J = 7.2 Hz, H-10), 7.25 (1H, t, J = 7.6, 7.2 Hz, H-9), 6.83 (1H, d, J = 9.6
Hz, H-1), 6.27 (1H, s, H-5), 5.63 (1H, d, J = 9.6 Hz, H-2), 2.58 (3H, s, CH3-11), 1.49, 1.49
(each 3H, s, CH3-3,3).
6.1.2.2. 6-Hydroxy-3,3,8-trimethylpyrano[2,3-c]xanthen-7(3H)-one (33f): 30.0% Yield
(starting from 1.0 g of crude 32f); 1H NMR δ 13.32 (1H, s, OH-6), 7.53 (1H, t, J = 8.0, 8.0
Hz, H-10), 7.30 (1H, d, J = 8.0 Hz, H-9), 7.11 (1H, d, J = 8.0 Hz, H-11), 6.82 (1H, d, J = 9.6
Hz, H-1), 6.24 (1H, s, H-5), 5.50 (1H, d, J = 9.6 Hz, H-2), 2.90 (3H, s, CH3-8), 1.48, 1.48
(each 3H, s, CH3-3,3).
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28.0% Yield (starting from 1.5 g of crude 32g); 1H NMR δ 12.93 (1H, s, OH-6), 7.81 (1H,
d, J = 8.4 Hz, H-8), 7.29 (1H, d, J = 8.0 Hz, H-10), 7.24 (1H, t, J = 8.4, 8.0 Hz, H-9), 6.92
(1H, d, J = 10.0 Hz, H-1), 6.28 (1H, s, H-5), 5.62 (1H, d, J = 10.0 Hz, H-2), 4.02 (3H, s,
OCH3-11), 1.48, 1.48 (each 3H, s, CH3-3,3).
6.1.2.4. 6-Hydroxy-3,3-dimethyl-10-methoxy-pyrano[2,3-c]xanthen-7(3H)-one (33h):
12.8% Yield (starting from 1.0 g of crude 32h); 1H NMR δ 13.07 (1H, s, OH-6), 8.11 (1H,
d, J = 9.3 Hz, H-8), 6.92 (1H, d, J = 9.3 Hz, H-9), 6.82 (1H, s, H-11), 6.81 (1H, d, J = 9.9
Hz, H-1), 6.24 (1H, s, H-5), 5.61 (1H, d, J = 9.9 Hz, H-2), 3.93 (3H, s, OCH3-10), 1.48, 1.48
(each 3H, s, CH3-3,3).
6.1.2.5. 6-Hydroxy-3,3-dimethyl-9-methoxy-pyrano[2,3-c]xanthen-7(3H)-one (33i):
42.0% Yield (starting from 2.0 g of crude 32i); 1H NMR δ 12.98 (1H, s, OH-6), 7.61 (1H, d,
J = 3.0 Hz, H-8), 7.41 (1H, d, J = 9.3 Hz, H-11), 7.32 (1H, dd, J = 9.3, 3.0 Hz, H-10), 6.84
(1H, d, J = 9.9 Hz, H-1), 6.27 (1H, s, H-5), 5.61 (1H, d, J = 9.9 Hz, H-2), 3.91 (3H, s,
OCH3-9), 1.49, 1.49 (each 3H, s, CH3-3,3).
6.1.2.6. 6,8-Dihydroxy-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-one (33k): 28.0% Yield
(starting from 1.0 g of crude 32k); 1H NMR δ 12.07, 11.95 (each 1H, s, OH-6,8), 7.56 (1H,
t, J = 8.1, 8.7 Hz, H-10), 6.90 (1H, d, J = 8.1 Hz, H-9), 6.81 (1H, d, J = 10.2 Hz, H-1), 6.79
(1H, d, J = 8.7 Hz, H-11), 6.26 (1H, s, H-5), 5.63 (1H, d, J = 10.2 Hz, H-2), 1.49, 1.49 (each
3H, s, CH3-3,3).
6.1.2.7. 6-Hydroxy-11-fluoro-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-one (33l): 30.0%
Yield (starting from 1.0 g of crude 32l); 1H NMR δ 12.77 (1H, s, OH-6), 8.01 (1H, d, J = 8.4
Hz, H-8), 7.51 (1H, t, J = 8.4, 9.6 Hz, H-9), 7.29 (1H, d, J = 9.6 Hz, H-10), 6.86 (1H, d, J =
10.4 Hz, H-1), 6.30 (1H, s, H-5), 5.63 (1H, d, J = 10.4 Hz, H-2), 1.50, 1.50 (each 3H, s,
CH3-3,3).
6.1.2.8. 6-Hydroxy-9-fluoro-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-one (33m): 20.0%
Yield (starting from 1.0 g of crude 32m); 1H NMR δ 12.77 (1H, s, OH-6), 7.90 (1H, dd, J =
8.0, 2.8 Hz, H-10), 7.43-7.46 (2H, m, H-8,11), 6.83 (1H, d, J = 10.0 Hz, H-1), 6.29 (1H, s,
H-5), 5.63 (1H, d, J = 10.0 Hz, H-2), 1.49, 1.49 (each 3H, s, CH3-3,3).
6.1.2.9. 6-Hydroxy-8-fluoro-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-one (33n): 46.0%
Yield (starting from 1.0 g of crude 32n); 1H NMR δ 12.94 (1H, s, OH-6), 7.64 (1H, t, J =
8.1, 8.4 Hz, H-10), 7.24 (1H, d, J = 8.4 Hz, H-11), 7.04 (1H, d, J = 8.1 Hz, H-9), 6.78 (1H,
d, J = 10.2 Hz, H-1), 6.25 (1H, s, H-5), 5.63 (1H, d, J = 10.2 Hz, H-2), 1.49, 1.49 (each 3H,
s, CH3-3,3).
6.1.2.10. 6-Hydroxy-10-bromo-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-one (33o):
50.0% Yield (starting from 1.8 g of crude 32o); 1H NMR δ 12.79 (1H, s, OH-6), 8.10 (1H,
d, J = 8.4 Hz, H-8), 7.67 (1H, s, H-11), 7.50 (1H, d, J = 8.4 Hz, H-9), 6.79 (1H, d, J = 10.0
Hz, H-1), 6.28 (1H, s, H-5), 5.64 (1H, d, J = 10.0 Hz, H-2), 1.49, 1.49 (each 3H, s,
CH3-3,3).
6.1.2.11. 6-Hydroxy-9-bromo-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-one (33p):
20.0% Yield (starting from 1.0 g of crude 32p); 1H NMR δ 12.72 (1H, s, OH-6), 8.24 (1H,
d, J = 2.4 Hz, H-8), 7.78 (1H, dd, J = 8.8, 2.4 Hz, H-10), 7.35 (1H, d, J = 8.8 Hz, H-11),
6.80 (1H, d, J = 6.4 Hz, H-1), 6.27 (1H, s, H-5), 5.63 (1H, d, J = 6.4 Hz, H-2), 1.49, 1.49
(each 3H, s, CH3-3,3).
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30.0% Yield (starting from 1.0 g of crude 32q); 1H NMR δ 13.44 (1H, s, OH-6), 6.76 (1H,
d, J = 10.0 Hz, H-1), 6.67 (1H, s, H-9), 6.62 (1H, s, H-11), 6.18 (1H, s, H-5), 5.56 (1H, d, J
= 10.0 Hz, H-2), 3.87 (3H, s, OCH3-10), 2.81 (3H, s, CH3-8), 1.45,1.45 (each 3H, s,
CH3-3,3).
6.1.3. Synthesis of 6-methoxy-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-ones
(34b-q)—A mixture of compound (33b-i, k-q) (1 equiv) and K2CO3 (3 equiv) in anhydrous
acetone (20 mL) was heated to reflux temperature for 3 h, then allowed to cool to rt. Methyl
iodide (2-3 equiv) was added at rt and the reaction was kept stirring overnight, monitored by
TLC. At completion, the reaction mixture was filtered, and the filtrate was evaporated to
dryness. The crude products 34j and 34n were carried directly to the dihydroxylation
reaction without purification. The remaining crude products were purified by column
chromatography using EtOAc and hexane to give compounds 34b-i, k-m and o-q.
6.1.3.1. 6-Methoxy-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-one (34b): 95% Yield
(starting from 150 mg of 33b); ESI+ (m/z, %), 309 (M+, 100); 1H NMR δ 8.29 (1H, d, J =
8.1 Hz, H-8), 7.62 (1H, t, J = 7.2, 7.8 Hz, H-10), 7.39 (1H, d, J = 7.8 Hz, H-11), 7.32 (1H, t,
J = 7.2, 8.1 Hz, H-9), 6.89 (1H, d, J = 9.9 Hz, H-1), 6.31 (1H, s, H-5), 5.62 (1H, d, J = 9.9
Hz, H-2), 3.98 (3H, s, OCH3-6), 1.50, 1.50 (each 3H, s, CH3-3,3).
6.1.3.2. 6-Methoxy-3,3,11-trimethylpyrano[2,3-c]xanthen-7(3H)-one (34c): 78% Yield
(starting from 300 mg of 33c); ESI+ (m/z, %), 323 (M++1, 100); 1H NMR δ 8.14 (1H, d, J =
7.6 Hz, H-8), 7.48 (1H, d, J = 7.6 Hz, H-10), 7.22 (1H, t, J = 7.6, 7.6 Hz, H-9), 6.88 (1H, d,
J = 9.6 Hz, H-1), 6.31 (1H, s, H-5), 5.62 (1H, d, J = 9.6 Hz, H-2), 3.98 (3H, s, OCH3-6),
2.54 (3H, s, CH3-11), 1.51, 1.51 (each 3H, s, CH3-3,3).
6.1.3.3. 6-Methoxy-3,3,10-trimethylpyrano[2,3-c]xanthen-7(3H)-one (34d): 100% Yield
(starting from 200 mg of 33d); ESI+ (m/z, %), 323 (M++1, 100); 1H NMR δ 8.17 (1H, d, J =
8.1 Hz, H-8), 7.20 (1H, s, H-11), 7.14 (1H, d, J = 8.1 Hz, H-9), 6.89 (1H, d, J = 9.9 Hz,
H-1), 6.30 (1H, s, H-5), 5.62 (1H, d, J = 9.9 Hz, H-2), 3.97 (3H, s, OCH3-6), 2.48 (3H, s,
CH3-10), 1.50, 1.50 (each 3H, s, CH3-3,3).
6.1.3.4. 6-Methoxy-3,3,9-trimethylpyrano[2,3-c]xanthen-7(3H)-one (34e): 86% Yield
(starting from 399 mg of 33e); ESI+ (m/z, %), 323 (M++1, 100); 1H NMR δ 8.06 (1H, s,
H-8), 7.45 (1H, d, J = 8.4 Hz, H-11), 7.31 (1H, d, J = 8.4 Hz, H-10), 6.90 (1H, d, J = 9.9 Hz,
H-1), 6.30 (1H, s, H-5), 5.62 (1H, d, J = 9.9 Hz, H-2), 3.98 (3H, s, OCH3-6), 2.45 (3H, s,
CH3-9), 1.50, 1.50 (each 3H, s, CH3-3,3).
6.1.3.5. 6-Methoxy-3,3,8-trimethylpyrano[2,3-c]xanthen-7(3H)-one (34f): 84% Yield
(starting from 700 mg of 33f); 1H NMR δ 7.45 (1H, t, J = 8.0, 7.6 Hz, H-10), 7.24 (1H, d, J
= 8.0 Hz, H-9), 7.06 (1H, d, J = 7.6 Hz, H-11), 6.87 (1H, d, J = 10.0 Hz, H-1), 6.28 (1H, s,
H-5), 5.60 (1H, d, J = 10.0 Hz, H-2), 3.98 (3H, s, OCH3-6), 2.90 (3H, s, CH3-8), 1.50, 1.50
(each 3H, s, CH3-3,3).
6.1.3.6. 6,11-Dimethoxy-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-one (34g): 40% Yield
(starting from 110 mg of 33g); ESI+ (m/z, %), 339 (M++1, 100); 1H NMR δ 7.87 (1H, d, J =
8.0 Hz, H-8), 7.24 (1H, t, J = 8.0, 8.0 Hz, H-9), 7,15 (1H, d, J = 8.0 Hz, H-10), 6.97 (1H, d,
J = 10.0 Hz, H-1), 6.32 (1H, s, H-5), 5.63 (1H, d, J = 10.0 Hz, H-2), 4.01, 3.98 (each 3H, s,
OCH3-6,11), 1.51, 1.51 (each 3H, s, CH3-3,3).
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6.1.3.7. 6,10-Dimethoxy-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-one (34h): 95% Yield
(starting from 110 mg of 33h); 1H NMR δ 8.17 (1H, d, J = 8.1 Hz, H-8), 7.20 (1H, s, H-11),
7.15 (1H, d, J = 8.1 Hz, H-9), 6.89 (1H, d, J = 9.9 Hz, H-1), 6.30 (1H, s, H-5), 5.62 (1H, d, J
= 9.9 Hz, H-2), 3.97 (3H, s, OCH3-6), 2.48 (3H, s, OCH3-10), 1.50. 1.50 (each 3H, s,
CH3-3,3).
6.1.3.8. 6,9-Dimethoxy-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-one (34i): 72% Yield
(starting from 400 mg of 33i); ESI+ (m/z, %), 377 (M++K, 100); 1H NMR δ 7.66 (1H, d, J =
3.0 Hz, H-8), 7.32 (1H, d, J = 9.0 Hz, H-11), 7.20 (1H, dd, J = 9.0, 3.0 Hz, H-10), 6.86 (1H,
d, J = 9.9 Hz, H-1), 6.27 (1H, s, H-5), 5.59 (1H, d, J = 9.9 Hz, H-2), 3.95 (3H, s, OCH3-6),
3.87 (3H, s, OCH3-9), 1.47, 1.47 (each 3H, s, CH3-3,3).
6.1.3.9. 6,8-Dimethoxy-3,3-dimethyl-pyrano[2,3-c]xanthen-7(3H)-one (34j): 80 mg crude
product was obtained from 100 mg of 33k.
6.1.3.10. 6-Methoxy-3,3-dimethyl-8-hydroxy-pyrano[2,3-c]xanthen-7(3H)-one (34k):
95% Yield (starting from 100 mg of 33k); 1H NMR δ 13.21 (1H, s, OH-8), 7.49 (1H, t, J =
8.4, 8.0 Hz, H-10), 6.85 (1H, d, J = 9.6 Hz, H-1), 6.83 (1H, d, J = 8.4 Hz, H-9), 6.74 (1H, d,
J = 8.0 Hz, H-11), 6.31 (1H, s, H-5), 5.63 (1H, d, J = 9.6 Hz, H-2), 4.03 (3H, s, OCH3-6),
1.51, 1.51 (each 3H, s, CH3-3,3).
6.1.3.11. 6-Methoxy-3,3-dimethyl-11-fluoro-pyrano[2,3-c]xanthen-7(3H)-one (34l): 40%
Yield (starting from 303 mg of 33l); 1H NMR δ 8.04 (1H, d, J = 8.4 Hz, H-8), 7.41 (1H, t, J
= 8.4, 9.6 Hz, H-9), 7.24 (1H, d, J = 9.6 Hz, H-10), 6.93 (1H, d, J = 10.0 Hz, H-1), 6.33 (1H,
s, H-5), 5.64 (1H, d, J = 10.0 Hz, H-2), 3.98 (3H, s, OCH3-6), 1.51, 1.51 (each 3H, s,
CH3-3,3).
6.1.3.12. 6-Methoxy-3,3-dimethyl-9-fluoro-pyrano[2,3-c]xanthen-7(3H)-one (34m): 61%
Yield (starting from 188 mg of 33m); 1H NMR δ 7.92 (1H, d, J = 8.4 Hz, H-10), 7.27-7.41
(2H, m, H-8,11), 6.87 (1H, d, J = 10.4 Hz, H-1), 6.31 (1H, s, H-5), 5.62 (1H, d, J = 10.4 Hz,
H-2), 3.98 (3H, s, OCH3-6), 1.51, 1.51 (each 3H, s, CH3-3,3).
6.1.3.13. 6-Methoxy-10-bromo-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-one (34o): 95%
Yield (starting from 295 mg of 33o); 1H NMR δ 8.13 (1H, d, J = 8.4 Hz, H-8), 7.60 (1H, s,
H-11), 7.44 (1H, d, J = 8.4 Hz, H-9), 6.83 (1H, d, J = 10.0 Hz, H-1), 6.31 (1H, s, H-5), 5.63
(1H, d, J = 10.0 Hz, H-2), 3.97 (3H, s, OCH3-6), 1.50, 1.50(each 3H, s, CH3-3,3).
6.1.3.14. 6-Methoxy-9-bromo-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-one (34p): 72%
Yield (starting from 70 mg of 33p); ESI+ (m/z, %), 387 (M+, 100); 1H NMR δ 8.36 (1H, d, J
= 2.4 Hz, H-8), 7.69 (1H, dd, J = 8.8, 2.4 Hz, H-10), 7.28 (1H, d, J = 8.8 Hz, H-11), 6.84
(1H, d, J = 10.0 Hz, H-1), 6.30 (1H, s, H-5), 5.61 (1H, d, J = 10.0 Hz, H-2), 3.96 (3H, s,
OCH3-6), 1.48, 1.48 (each 3H, s, CH3-3,3).
6.1.3.15. 6,10-Dimethoxy-3,3,8-trimethylpyrano[2,3-c]xanthen-7(3H)-one (34q): 54%
Yield (starting from 295 mg of 33q); 1H NMR δ 6.85 (1H, d, J = 10.0 Hz, H-1), 6.67 (1H, s,
H-9), 6.63 (1H, s, H-11), 6.28 (1H, s, H-5), 5.59 (1H, d, J = 10.0 Hz, H-2), 3.96 (3H, s,
OCH3-6), 3.88 (3H, s, OCH3-10), 2.86 (3H, s, CH3-8), 1.49, 1.49 (each 3H, s, CH3-3,3).
6.1.4. General procedure for the preparation of 35a-q and 38-39—A mixture of
K3Fe(CN)6 (3 equiv), K2CO3 (3 equiv), (DHQ)2-PYR (2% equiv), and K2OsO2(OH)4 (2%
equiv) was dissolved in t-BuOH/H2O (v/v, 1:1) at rt. The solution was cooled to 0 °C and
methanesulfonamide (1 equiv) was added with stirring. After 20 min, substituted
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pyranochromone (34a-q, and 36-37) was added. The mixture was stirred at 0 °C for 1-2
days, monitored by TLC. At completion, Na2S2O5 (excess), water and CH2Cl2 were added,
and stirring was continued for 1 h at rt. The mixture was extracted with CH2Cl2 three times,
and the combined organic layer was dried over MgSO4. The solvent was removed under
reduced pressure, and the residue was purified by column chromatography with
hexanes:EtOAc = 3:7 to afford the pure substituted (+)-cis-3',4'-
dihydroxypyranoxanthenones (35a-b, d-f, h-n, p-q). Crude compounds 35c, 35g, 35o, and
38-39 were carried to the next step without purification.
6.1.4.1. (1R,2R)-1,2-Dihydroxy-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-one (35a):
22% Yield (starting from 70 mg of 34a); ESI+ (m/z, %), 313 (M++1, 100); 1H NMR δ 8.35
(1H, d, J = 7.8 Hz, H-8), 8.20 (1H, d, J = 9.3 Hz, H-6), 7.71 (1H, t, J = 8.1, 8.1 Hz, H-10),
7.49 (1H, d, J = 8.1 Hz, H-11), 7.41 (1H, t, J = 8.1, 7.8 Hz, H-9), 6.89 (1H, d, J = 9.3 Hz,
H-5), 5.35 (1H, d, J = 5.4 Hz, H-1), 3.93 (1H, br, H-2), 3.34, 3.10 (each 1H, br, OH-1,2),
1.52, 1.46 (each 3H, s, CH3-3,3).
6.1.4.2. (1R,2R)-1,2-Dihydroxy-6-methoxy-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-
one (35b): 75% Yield (starting from 188 mg of 34b); ESI+ (m/z, %), 343 (M+, 100); 1H
NMR δ 8.30 (1H, d, J = 7.8 Hz, H-8), 7.63 (1H, t, J = 6.9, 8.1 Hz, H-10), 7.38 (1H, d, J =
8.1 Hz, H-11), 7.36 (1H, t, J = 7.8, 6.9 Hz, H-9), 6.30 (1H, s, H-5), 5.25 (1H, br, H-1), 3.95
(3H, s, OCH3-6), 3.89 (1H, br, H-2), 3.37, 3.24 (each 1H, br, OH-1,2), 1.52, 1.48 (each 3H,
s, CH3-3,3).
6.1.4.3. (1R,2R)-1,2-Dihydroxy-6-methoxy-3,3,10-trimethylpyrano[2,3-
c]xanthen-7(3H)-one (35d): 45% Yield (starting from 200 mg of 34d); 1H NMR δ 8.15
(1H, d, J = 8.4 Hz, H-8), 7.14-7.16 (2H, br, H-9,11), 6.27 (1H, s, H-5), 5.23 (1H, br, H-1),
3.94 (3H, s, OCH3-6), 3.88 (1H, s, H-2), 3.55 (H, d, J = 3.6 Hz, OH-1), 3.30 (1H, d, J = 6.9
Hz, OH-2), 2.46 (3H, s, CH3-10), 1.55, 1.49 (each 3H, s, CH3-3,3).
6.1.4.4. (1R,2R)-1,2-Dihydroxy-6-methoxy-3,3,9-trimethylpyrano[2,3-c]xanthen-7(3H)-
one (35e): 59% Yield (starting from 250 mg of 34e); 1H NMR δ 7.97 (1H, s, H-8), 7.34 (1H,
d, J = 8.4 Hz, H-10), 7.19 (1H, d, J = 8.4 Hz, H-11), 6.20 (1H, s, H-5), 5.20 (1H, t, J = 4.5,
4.5 Hz, H-1), 3.90 (3H, s, OCH3-6), 3.87 (1H, t, J = 4.5, 4.5 Hz, H-2), 3.84 (1H, d, J = 4.5
Hz, OH-1), 3.47 (1H, d, J = 4.5 Hz, OH-2), 2.42 (3H, s, CH3-9), 1.55, 1.48 (each 3H, s,
CH3-3,3),
6.1.4.5. (1R,2R)-1,2-Dihydroxy-6-methoxy-3,3,8-trimethylpyrano[2,3-c]xanthen-7(3H)-
one (35f): 40% Yield (starting from 180 mg of 34f); ESI+ (m/z, %), 357 (M++1, 100); 1H
NMR δ 7.42 (1H, t, J = 8.4, 7.6 Hz, H-10), 7.20 (1H, d, J = 8.4 Hz, H-9), 7.07 (1H, d, J =
7.6 Hz, H-11), 6.26 (1H, s, H-5), 5.22 (1H, d, J = 4.8 Hz, H-1), 3.95 (3H, s, OCH3-6), 3.87
(1H, d, J = 4.8 Hz, H-2), 3.32, 3.22 (each 1H, s, OH-1,2), 2.05 (3H, s, CH3-8), 1.50, 1.46
(each 3H, s, CH3-3,3).
6.1.4.6. (1R,2R)-1,2-Dihydroxy-6,11-dimethoxy-3,3-dimethylpyrano[2,3-
c]xanthen-7(3H)-one (35g): Starting from 35 mg of crude 34g; ESI+ (m/z, %), 339 (M++1,
100); ESI+ (m/z, %), 373 (M++1, 100).
6.1.4.7. (1R,2R)-6,10-Methoxy-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-one (35h): 30%
Yield (starting from 110 mg of 34h); ESI+ (m/z, %), 373 (M++1, 100); 1H NMR δ 8.18 (1H,
d, J = 8.7 Hz, H-8), 6.90 (1H, d, J = 8.7 Hz, H-9), 6.71 (1H, s, H-11), 6.26 (1H, s, H-5), 5.20
(1H, br, H-1), 3.92 (3H, s, OCH3-6), 3.90 (3H, s, OCH3-10), 3.50 (1H, br, H-2), 3.30 (2H,
br, OH-1,2), 1.55, 1.48 (each 3H, s, CH3-3,3),
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c]xanthen-7(3H)-one (35i): 40% Yield (starting from 200 mg of 34i); ESI+ (m/z, %), 373
(M++1, 100); 1H NMR δ 7.65 (1H, s, H-8), 7.31 (1H, d, J = 9.0 Hz, H-11), 7.22 (1H, d, J =
9.0 Hz, H-10), 6.27 (1H, s, H-5), 5.23 (1H, br, H-1), 3.94 (3H, s, OCH3-6), 3.90 (3H, s,
OCH3-9), 3.35 (1H, br, H-2), 3.23, 3,23 (each 1H, s, OH-1,2), 1.51, 1.46 (each 3H, s,
CH3-3,3).
6.1.4.9. (1R,2R)-1,2-Dihydroxy-6,8-dimethoxy-3,3-dimethylpyrano[2,3-
c]xanthen-7(3H)-one (35j): 50% Yield (starting from 60 mg of 34j); ESI+ (m/z, %), 373
(M++1, 100); 1H NMR δ 7.51 (1H, t, J = 8.7, 8.4 Hz, H-10), 6.96 (1H, d, J = 8.7 Hz, H-11),
6.79 (1H, d, J = 8.4 Hz, H-9), 6.26 (1H, s, H-5), 5.22 (1H, br, H-1), 3.97, 3.91 (each 3H, s,
OCH3-6,8), 3.19 (1H, br, H-2), 1.49, 1.45 (each 3H, s, CH3-3,3).
6.1.4.10. (1R,2R)-1,2-Dihydroxy-6-methoxy-8-hydroxy-3,3-dimethylpyrano[2,3-
c]xanthen-7(3H)-one (35k): 45% Yield (starting from 50 mg of 34k); ESI+ (m/z, %), 357
(M++1, 100); 1H NMR δ 13.14 (1H, s, OH-8), 7.52 (1H, t, J = 8.4, 8.4 Hz, H-10), 6.96 (1H,
d, J = 8.4 Hz, H-9), 6.79 (1H, d, J = 8.4 Hz, H-11), 6.32 (1H, s, H-5), 5.23 (1H, d, J = 4.8
Hz, H-1), 3.99 (3H, s, OCH3-6), 3.89 (1H, d, J = 4.8 Hz, H-2), 3.11, 3.10 (each 1H, s,
OH-1,2), 1.50, 1.47 (each 3H, s, CH3-3,3).
6.1.4.11. (1R,2R)-1,2-Dihydroxy-6-methoxy-11-fluoro-3,3-dimethylpyrano[2,3-
c]xanthen-7(3H)-one (35l): 50% Yield (starting from 107 mg of 34l); ESI+ (m/z, %), 361
(M++1, 100); 1H NMR δ 8.06 (1H, d, J = 8.0 Hz, H-8), 7.44 (1H, t, J = 8.0, 9.6 Hz, H-9),
7.30 (1H, d, J = 9.6 Hz, H-10), 6.34 (1H, s, H-5), 5.29 (1H, d, J = 4.4 Hz, H-1), 3.98 (3H, s,
OCH3-6), 3.91 (1H, s, OH-1), 3.39 (1H, d, J = 4.4Hz, H-2), 3.21 (1H, s, OH-2), 1.51, 1.46
(each 3H, s, CH3-3,3).
6.1.4.12. (1R,2R)-1,2-Dihydroxy-6-methoxy-9-fluoro-3,3-dimethylpyrano[2,3-
c]xanthen-7(3H)-one (35m): 50% Yield (starting from 110 mg of 34m); ESI+ (m/z, %),
361 (M++1, 100); 1H NMR δ 7.92 (1H, d, J = 8.4 Hz, H-10), 7.56 (1H, m, H-8), 7.39 (1H,
m, H-11), 6.34 (1H, d, J = 4.0 Hz, H-1), 6.33 (1H, s, H-5), 5.24 (1H, d, J = 4.0 Hz, H-2),
3.97 (2H, s, OCH3-6), 3.60, 3.40 (each 1H, s, OH-1,2), 1.49, 1.47 (each 3H, s, CH3-3,3).
6.1.4.13. (1R,2R)-1,2-Dihydroxy-6-methoxy-8-fluoro-3,3-dimethylpyrano[2,3-
c]xanthen-7(3H)-one (35n): 60% Yield (starting from 50 mg of 34n); ESI+ (m/z, %), 361
(M++1, 100); 1H NMR δ 7.56 (1H, d, J = 9.0 Hz, H-11), 7.21 (1H, d, J = 9.0 Hz, H-9), 6.98
(1H, t, J = 9.0, 9.0 Hz, H-10), 6.28 (1H, s, H-5), 5.2 (1H, br, H-1), 3.93 (3H, s, OCH3-6),
3.90 (1H, br, H-2), 3.12, 3.11 (each 1H, s, OH-1,2), 1.50, 1.57 (each 3H, s, CH3-3,3).
6.1.4.14. (1R,2R)-1,2-Dihydroxy-6-methoxy-9-bromo-3,3-dimethylpyrano[2,3-
c]xanthen-7(3H)-one (35p): 45% Yield (starting from 50 mg of 34p); ESI+ (m/z, %), 421
(M+, 100); 1H NMR δ 8.34 (1H, d, J = 1.6 Hz, H-8), 7.69 (1H, dd, J = 8.8, 1.6 Hz, H-10),
7.25 (1H, d, J = 8.8 Hz, H-11), 6.27 (1H, s, H-5), 5.20 (1H, d, J = 4.4 Hz, H-1), 3.92 (3H, s,
OCH3-6), 3.86 (1H, d, J = 4.4 Hz, H-2), 3.20, 3.12 (each 1H, s, OH-1,2), 1.49, 1.45 (each
3H, s, CH3-3,3).
6.1.4.15. (1R,2R)-1,2-Dihydroxy-6,10-dimethoxy-3,3,8-trimethylpyrano[2,3-
c]xanthen-7(3H)-one (35q): 50% Yield (starting from 50 mg of 34q); 1H NMR δ 6.67 (1H,
s, H-9), 6.67 (1H, s, H-11), 6.28 (1H, s, H-5), 5.23 (1H, d, J = 4.4 Hz, H-1), 4.10 (1H, d, J =
4.4 Hz, H-2), 3.93 (3H, s, OCH3-6), 3.89 (3H, s, OCH3-10), 3.13, 3.11 (each 1H, s, OH-1,2),
2.87 (3H, s, CH3-8), 1.49, 1.46 (each 3H, s, CH3-3,3).
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A mixture of 34o (10 mg, 0.025 mmoL), zinc cyanide (3.5 mg, 0.03 mmoL) and Pd(PPh3)4
(12 mg, 0.011 mmoL) was dissolved in anhydrous DMF (0.5 mL) and heated to 130 °C for
16 h, monitored by TLC. At completion, the reaction mixture was filtered through Celite,
and the crude product was purified by PTLC with EtOAc:hexane = 1:3 to afford pure 36 as
yellow solid. 90% yield; MS-ESI+ (m/z, %) 334 (M+ + 1, 100); 1H NMR δ 8.35 (1H, d, J =
8.0 Hz, H-8), 7.72 (1H, s, H-11), 7.55 (1H, d, J = 8.0 Hz, H-9), 6.82 (1H, d, J = 10.0 Hz,
H-1), 6.32 (1H, s, H-5), 5.64 (1H, d, J = 10.0 Hz, H-2), 3.96 (3H, s, OCH3-6), 1.57, 1.49
(each 3H, s, CH3-2,2).
6.1.6. 6-Methoxy-9-cyano-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-one (37)—
The procedure was identical to that used for the preparation of 36. The crude 37 was carried
to the next step without purification. MS-ESI+ (m/z, %) 334 (M+ + 1, 100).
6.1.7. General procedure for the preparation of 6-7, 10-24, 18 and 28-29—The
substituted 1R,2R-dihydroxypyranoxanthone (35a-q, 38-39) (1 equiv), (S)-(-)-camphanoyl
chloride (3 equiv), and DMAP (4 equiv) were stirred in CH2Cl2 for 1-2 h at rt, monitored by
TLC. At completion, the mixture was diluted with CH2Cl2 and washed separately with
water and brine. The solvent was then removed under reduced pressure and the residue was
purified by PTLC with hexanes:EtOAc = 3:2 to afford the appropriately substituted 1R,2R-
di-O-(-)-camphanoyl-3,3-dimethyldihydroprano[2,3-c]xanthone (6-7, 10-24, and 28-29).
6.1.7.1. 1R,2R-(-)-Dicamphanoyl-3,3-dimethyl-1,2-dihydropyrano[2,3-c]xanthen-7(1H)-
one (6): 85% Yield (starting from 15 mg of 35a); white solid; mp 146-148 °C; 1H NMR δ
8.33 (1H, d, J = 7.8 Hz, H-8), 8.31 (1H, d, J = 9.0 Hz, H-6), 7.67 (1H, t, J = 7.2, 8.4 Hz,
H-10), 7.39 (1H, t, J = 7.2, 7.8 Hz, H-9), 7.35 (1H, d, J = 8.4 Hz, H-11), 6.94 (1H, d, J = 9.0
Hz, H-5), 6.93 (1H, d, J = 4.5 Hz, H-1), 5.43 (1H, d, J = 4.5 Hz, H-2), 2.52, 2.322 1.90, 1.75
(each 2H, m, camphanoyl-CH2), 1.57, 1.50 (each 3H, s, CH3-3,3), 1.14, 1.12, 1.03, 1.00,
0.93, 0.89 (each 3H, s, camphanoyl-CH3); [α]D -22.7° (c = 0.0015, CH3Cl); HRMS for (M+
+ Na): calcd m/z 695.2469, found: 695.2485.
6.1.7.2. 1R,2R-(-)-Dicamphanoyl-3,3-dimethyl-6-methoxy-1,2-dihydropyrano[2,3-
c]xanthen-7(1H)-one (7): 88% Yield (starting from 52 mg of 35b); white solid; mp
134-135 °C; 1H NMR δ 8.40 (1H, d, J = 7.8 Hz, H-8), 7.72 (1H, t, J = 7.5, 8.1 Hz, H-10),
7.46 (1H, t, J = 7.8, 7.5 Hz, H-9), 7.39 (1H, d, J = 8.1 Hz, H-11), 6.98 (1H, d, J = 4.5 Hz,
H-1), 6.46 (1H, s, H-5), 5.53 (1H, d, J = 4.5 Hz, H-2), 4.12 (3H, s, OCH3-6), 2.60, 2.33,
2.10, 1.80 (each 2H, m, camphanoyl-CH2), 1.69, 1.61 (each 3H, s, CH3-3,3), 1.25, 1.25,
1.15, 1.12, 1.02, 1.01 (each 3H, s, camphanoyl-CH3); [α]D -40.9° (c = 0.0069, CH3Cl);
HRMS for (M+ + Na): calcd m/z 725.2574, found: 725.2603; 13C NMR: δ 9.78, 9.92, 16.74,
16.85, 16.93, 17.01, 21.53, 27.12, 29.20, 29.18, 31.00, 31.54, 54.59, 54.94, 55.15, 55.20,
61.57, 72.86, 72.82, 90.95, 91.49, 96.01, 96.06, 98.66, 107.82, 117.24, 123.20, 124.76,
127.06, 134.20, 154.47, 157.60, 159.07, 163.39, 167.17, 167.65, 175.13, 178.11, 178.18.
6.1.7.3. 1R,2R-(-)-Dicamphanoyl-3,3,11-trimethyl-6-methoxy-1,2-dihydropyrano[2,3-
c]xanthen-7(1H)-one (10): 85% Yield (starting from 41 mg of 35c); white solid; mp
174-175 °C; 1H NMR δ 8.12 (1H, d, J = 7.6 Hz, H-8), 7.36 (1H, d, J = 7.2 Hz, H-10), 7.24
(1H, t, J = 7.6, 7.2 Hz, H-9), 6.87 (1H, d, J = 4.4 Hz, H-1), 6.34 (1H, s, H-5), 5.44 (1H, d, J
= 4.4 Hz, H-2), 4.01 (3H, s, OCH3-6), 2.45, 2.25, 1.90, 1.67 (each 2H, m, camphanoyl-
CH2), 2.39 (3H, s, CH3-11), 1.60, 1.49 (each 3H, s, CH3-3,3), 1.14, 1.14, 1.03, 1.00, 0.93,
0.89 (each 3H, s, camphanoyl-CH3); [α]D -40.9 ° (c = 0.0069, CH3Cl); [α]D -42.5° (c =
0.0051, CH3Cl); HRMS for (M+ + Na): calcd m/z 739.2731, found: 739.2736.
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c]xanthen-7(1H)-one (11): 80% Yield (starting from 50 mg of 35d); white solid; mp
174-175 °C; 1H NMR δ 8.15 (1H, d, J = 8.1 Hz, H-8), 7.13 (1H, d, J = 8.1 Hz, H-9), 7.07
(1H, s, H-11), 6.87 (1H, d, J = 4.8 Hz, H-1), 6.32 (1H, s, H-5), 5.39 (1H, d, J = 4.8 Hz, H-2),
3.99 (3H, s, OCH3-6), 2.41 (3H, s, CH3-10), 2.45, 2.20, 1.95, 1.80 (each 2H, m,
camphanoyl-CH2), 1.56, 1.49 (each 3H, s, CH3-3,3), 1.14, 1.13, 1.04, 1.00, 0.90, 0.87 (each
3H, s, camphanoyl-CH3); [α]D -37.2° (c = 0.0018, CH3Cl); HRMS for (M+ + Na): calcd m/z
739.2731, found: 739.2724.
6.1.7.5. 1R,2R-(-)-Dicamphanoyl-3,3,9-trimethyl-6-methoxy-1,2-dihydropyrano[2,3-
c]xanthen-7(1H)-one (12): 77% Yield (starting from 100 mg of 35e); light yellow solid; mp
179-180 °C; 1H NMR δ 8.05 (1H, s, H-8), 7.41 (1H, d, J = 8.7 Hz, H-11), 7.18 (1H, d, J =
8.7 Hz, H-10), 6.86 (1H, d, J = 4.5 Hz, H-1), 6.32 (1H, s, H-5), 5.40 (1H, d, J = 4.5 Hz,
H-2), 4.00 (3H, s, OCH3-6), 2.44 (3H, s, CH3-9), 2.45, 2.20, 1.90, 1.70 (each 2H, m,
camphanoyl-CH2), 1.57, 1.49 (each 3H, s, CH3-3,3), 1.14, 1.13, 1.03, 1.00, 0.90, 0.88 (each
3H, s, camphanoyl-CH3); [α]D -34.6° (c = 0.0028, CH3Cl); HRMS for (M+ + Na): calcd m/z
739.2731, found: 739.2724.
6.1.7.6. 1R,2R-(-)-Dicamphanoyl-3,3,8-trimethyl-6-methoxy-1,2-dihydropyrano[2,3-
c]xanthen-7(1H)-one (13): 75% Yield (starting from 70 mg of 35f); white solid; mp
240-242 °C; 1H NMR δ 7.39 (1H, t, J = 8.4, 7.6 Hz, H-10), 7.09 (1H, d, J = 8.4 Hz, H-9),
7.06 (1H, d, J = 7.6 Hz, H-11), 6.82 (1H, d, J = 4.8 Hz, H-1), 6.29 (1H, s, H-5), 5.37 (1H, d,
J = 4.8 Hz, H-2), 3.98 (3H, s, OCH3-6), 2,86 (3H, s, CH3-8), 2.46, 2.18, 1.90, 1.65 (each
2H, m, camphanoyl CH2), 1.56, 1.55 (each 3H, s, CH3-3,3), 1.11, 1.10, 1.01, 1.00, 0.88,
0.86 (each 3H, s, camphanoyl CH3); [α]D -29.3° (c = 0.003, CH3Cl); HRMS for (M+ + Na):
calcd m/z 739.2731, found: 739.2713.
6.1.7.7. 1R,2R-(-)-Dicamphanoyl-3,3-dimethyl-6,11-dimethoxy-1,2-dihydropyrano[2,3-
c]xanthen-7(1H)-one (14): 53% Yield (starting from 25 mg of 35g); white solid; mp
179-180 °C; 1H NMR δ 7.82 (1H, d, J = 8.0 Hz, H-8), 7.25 (1H, t, J = 8.0, 8.0 Hz, H-9),
7.09 (1H, d, J = 8.0 Hz, H-10), 6.82 (1H, d, J = 4.4 Hz, H-1), 6.33 (1H, s, H-5), 5.44 (1H, d,
J = 4.4 Hz, H-2), 4.00, 3.91 (each 3H, s, OCH3-6,11), 2.44, 2.27, 1.95, 1,70 (each 2H, m,
camphanoyl-CH2), 1.57, 1.47 (each 3H, s, CH3-3,3), 1.13, 1.13, 1.03, 1.01, 0.91, 0.87 (each
3H, s, camphanoyl-CH3); [α]D -40.8° (c = 0.0013, CH3Cl); HRMS for (M+ + Na): calcd m/z
755.2680, found: 755.2660.
6.1.7.8. 1R,2R-(-)-Dicamphanoyl-3,3-dimethyl-6,10-dimethoxy-1,2-dihydropyrano[2,3-
c]xanthen-7(1H)-one (15): 43% Yield (starting from 10 mg of 35h); white solid; mp
177-178 °C; 1H NMR δ 8.12 (1H, d, J = 8.7 Hz, H-8), 6.84 (1H, dd, J = 8.7, 2.4 Hz, H-9),
6.79 (1H, d, J = 4.5 Hz, H-1), 6.59 (1H, d, J = 2.4 Hz, H-11), 6.26 (1H, s, H-5), 5.33 (1H, d,
J = 4.5 Hz, H-2), 3.92 (3H, s, OCH3-6), 3.77 (3H, s, OCH3-10), 2.40, 2.15, 1.95, 1.65 (each
2H, m, camphanoyl-CH2), 1.50, 1.42 (each 3H, s, CH3-3,3), 1.07, 1.06, 0.97, 0.93, 0.85,
0.81 (each 3H, s, camphanoyl-CH3); [α]D -16.2° (c = 0.0052, CH3Cl); HRMS for (M+ + 1):
calcd m/z 733.2860, found: 733.2874.
6.1.7.9. 1R,2R-(-)-Dicamphanoyl-3,3-dimethyl-6,9-dimethoxy-1,2-dihydropyrano[2,3-
c]xanthen-7(1H)-one (16): 60% Yield (starting from 20 mg of 35i); white solid; mp
168-170 °C; ESI+ (m/z, %), 732 (M+, 100); 1H NMR δ 7.66 (1H, s, H-8), 7.21, 7.21 (each
1H, d, H = 9.2 Hz, H-10,11), 6.85 (1H, d, J = 4.8 Hz, H-1), 6.32 (1H, s, H-5), 5.40 (1H, d, J
= 4.8 Hz, H-2), 4.00 (3H, s, OCH3-6), 3.88 (3H, s, OCH3-9), 2.5, 2.20, 1.90, 1.70 (each 2H,
m, camphanoyl-CH2), 1.57, 1.49 (each 3H, s, CH3-3,3), 1.14, 1.13, 1.03, 1.00, 0.90, 0.88
(each 3H, s, camphanoyl-CH3); [α]D -35.3° (c = 0.0024, CHCl3); HRMS for (M+ + 1): calcd
m/z 733.2860, found: 733.2864.
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c]xanthen-7(1H)-one (17): 52% Yield (starting from 10 mg of 35j); white solid; mp
155-156 °C; 1H NMR δ 7.44 (1H, t, J = 8.4, 8.4 Hz, H-10), 6.82 (1H, d, J = 8.4 Hz, H-11),
6.80 (1H, d, J = 4.4 Hz, H-1), 6.75 (1H, d, J = 8.4 Hz, H-9), 6.27 (1H, s, H-5), 5.36 (1H, d, J
= 4.4 Hz, H-2), 3.94, 3.93 (each 3H, s, OCH3-6.8), 2.50, 2.20, 1.90, 1.70 (each 2H,
camphanoyl-CH2), 1.54, 1.46 (each 3H, s, CH3-3,3), 1.13, 1.11, 1.03, 1.00, 0.88, 0.85 (each
3H, s, camphanoyl-CH3); [α]D -131.7° (c = 0.003, CHCl3); HRMS for (M+ + Na): calcd m/z
755.2680, found: 755.2671.
6.1.7.11. 1R,2R-(-)-Dicamphanoyl-3,3,8-trimethyl-6,10-dimethoxy-1,2-
dihydropyrano[2,3-c]xanthen-7(1H)-one (18): 52% Yield (starting from 10 mg of 35q);
white solid; mp 183-184 °C; 1H NMR δ 6.85 (1H, d, J = 4.8 Hz, H-1), 6.64 (1H, d, J = 2.4
Hz, H-9), 6.53 (1H, d, J = 2.4 Hz, H-11), 6.30 (1H, s, H-5), 5.39 (1H, d, J = 4.8 Hz, H-2),
3.99 (3H, s, OCH3-6), 3.81 (3H, s, OCH3-10), 2.84 (3H, s, CH3-8), 2.45, 2.20, 1.90, 1.70
(each 2H, m, camphanoyl CH2), 1.56, 1.48 (each 3H, s, CH3-3,3), 1.13, 1.13, 1.04, 1.00,
0.91, 0.88 (each 2H, s, camphanoyl CH3); [α]D -23.6° (c = 0.0012, CHCl3); HRMS for (M+
+ Na): calcd m/z 769.2836, found: 769.2835.
6.1.7.12. 1R,2R-(-)-Dicamphanoyl-3,3-dimethyl-6-methoxy-8-hydroxy-1,2-
dihydropyrano[2,3-c]xanthen-7(1H)-one (19): 30% Yield (starting from 10 mg of 35k);
white solid; mp 155-157 °C; 1H NMR δ 12.94 (1H, s, OH-8), 7.43 (1H, t, J = 8.0, 8.4 Hz,
H-10), 6.78 (1H, d, J = 4.8 Hz, H-1), 6.74 (1H, d, J = 8.0 Hz, H-9), 6.67 (1H, d, J = 8.4 Hz,
H-11), 6.31 (1H, s, H-5), 5.36 (1H, d, J= 4.8 Hz, H-2), 3.99 (3H, s, OCH3-6), 2,45, 2.18,
1.90, 1.65 (each 2H, m, camphanoyl-CH2), 1.52, 1.45 (each 3H, s, CH3-3,3), 1.10, 1.09,
1.00, 0.96, 0.91, 0.88 (each 2H, s, camphanoyl-CH3); [α]D -62.5° (c = 0.0018, CHCl3);
HRMS for (M+ + Na): calcd m/z 741.2523, found: 741.2528.
6.1.7.13. 1R,2R-(-)-Dicamphanoyl-3,3-trimethyl-6-methoxy-11-fluoro-1,2-
dihydropyrano[2,3-c]xanthen-7(1H)-one (20): 80% Yield (starting from 45 mg of 35l);
white solid; mp 183-184 °C; 1H NMR δ 8.05 (1H, d, J = 8.0 Hz, H-8), 7.39 (1H, t, J = 8.0,
8.4 Hz, H-9), 7.28 (1H, d, J = 8.4 Hz, H-10), 6.76 (1H, d, J = 4.4 Hz, H-1), 6.36 (1H, s,
H-5), 5.43 (1H, d, J = 4.4 Hz, H-2), 4.01 (3H, s, OCH3-6), 2.51, 2.20, 1.92, 1.75 (each 2H,
m, camphanoyl-CH2), 1.58, 1.48 (each 3H, s, CH3-3,3), 1.13, 1.13, 1.06, 1.04, 1.00, 0.99
(each 3H, s, camphanoyl-CH3); [α]D -41.2° (c = 0.0052, CHCl3); HRMS for (M+ + Na):
calcd m/z 743.2480, found: 743.2483.
6.1.7.14. 1R,2R-(-)-Dicamphanoyl-3,3-trimethyl-6-methoxy-9-fluoro-1,2-
dihydropyrano[2,3-c]xanthen-7(1H)-one (21): 48% Yield (starting from 45 mg of 35m);
white solid; mp 204-205 °C; 1H NMR δ 7.92 (1H, d, J = 8.0 Hz, H-10), 7.28-7.36 (2H, m,
H-9,11), 6.85 (1H, d, J = 4.4 Hz, H-1), 6.35 (1H, s, H-5), 5.40 (1H, d, J = 4.4 Hz, H-2), 4.00
(3H, s, OCH3-6), 2.49, 2.19, 1.90, 1.68 (each 2H, m, camphanoyl-CH2), 1.56, 1.49 (each
3H, s, CH3-3,3), 1.14, 1.13, 1.04, 1.00, 0.90, 0.90 (each 3H, s, camphanoyl-CH3); [α]D
-23.6° (c = 0.0025, CHCl3); HRMS for (M+ + Na): calcd m/z 743.2480, found: 743.2469.
6.1.7.15. 1R,2R-(-)-Dicamphanoyl-3,3-trimethyl-6-methoxy-8-fluoro-1,2-
dihydropyrano[2,3-c]xanthen-7(1H)-one (22): 80% Yield (starting from 5 mg of 35n);
white solid; mp 148-150 °C; 1H NMR δ 7.44 (1H, t, J = 8.7, 8.4 Hz, H-10), 7.01 (1H, d, J =
8.4 Hz, H-11), 6.92 (1H, d, J = 8.7 Hz, H-9), 6.76 (1H, d, J = 4.5 Hz, H-1), 6.26 (1H, s,
H-5), 5.32 (1H, d, J = 4.5 Hz, H-2), 3.91 (3H, s, OCH3-6), 2.40, 2.12, 1.91, 1.67 (each 2H,
m, camphanoyl-CH2), 1.51, 1.42 (each 3H, s, CH3-3,3), 1.07, 1.05, 0.97, 0.93, 0.83, 0.83
(each 3H, s, camphanoyl-CH3); [α]D -17.1° (c = 0.0035, CHCl3), HRMS for (M+ + Na):
calcd m/z 743.2480, found: 743.2476.
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dihydropyrano[2,3-c]xanthen-7(1H)-one (23): 52% Yield (starting from 35 mg of 35o);
white solid; mp 159-160 °C; 1H NMR δ 8.11 (1H, d, J = 8.4 Hz, H-8), 7.48 (1H, d, J = 1.6
Hz, H-11), 7.44 (1H, dd, J = 8.4 Hz, H-9), 6.80 (1H, d, J = 4.8 Hz, H-1), 6.32 (1H, s, H-5),
5.46 (1H, d, J = 4.8 Hz, H-2), 3.97 (3H, s, OCH3-6), 2.45, 2.08, 1.90, 1.70 (each 2H, m,
camphanoyl CH2), 1.61, 1.61 (each 3H, s, CH3-3,3), 1.46, 1.14, 1.12, 1.05, 1.04, 1.02 (each
3H, s, camphanoyl CH3); [α]D -25.3° (c = 0.0035, CHCl3); HRMS for (M+ + Na): calcd m/z
803.1679, found: 803.1691.
6.1.7.17. 1R,2R-(-)-Dicamphanoyl-3,3-dimethyl-9-bromo-6-methoxy-1,2-
dihydropyrano[2,3-c]xanthen-7(1H)-one (24): 50% Yield (starting from 10 mg of 35p);
white solid; mp 159-160 °C; 1H NMR δ 8.35 (1H, d, J = 2.8 Hz, H-8), 7.67 (1H, dd, J = 8.8,
2.8 Hz, H-10), 7.20 (1H, d, J = 8.8 Hz, H-11), 6.81 (1H, d, J = 4.4 Hz, H-1), 6.32 (1H, s,
H-5), 5.47 (1H, d, J = 4.4 Hz, H-2), 3.98 (3H, s, OCH3-6), 2.40, 2,10, 1.90, 1.60 (each 2H,
m, camphanoyl-CH2), 1.56, 1.46 (each 3H, s, CH3-3,3), 1.14, 1.12, 1.03, 1.02, 1.01, 0.77
(each 3H, s, camphanoyl-CH3); [α]D -13.0° (c = 0.004, CHCl3); HRMS for (M+ + Na):
calcd m/z 803.1679, found: 803.1684.
6.1.7.18. 1R,2R-(-)-Dicamphanoyl-3,3-dimethyl-6-methoxy-10-cyano-1,2-
dihydropyrano[2,3-c]xanthen-7(1H)-one (28): 80% Yield (starting from 36 mg of 36);
white solid; mp 164-165 °C; 1H NMR δ 8.36 (1H, d, J = 8.0 Hz, H-8), 7.60 (1H, d, J = 8.0
Hz, H-9), 7.55 (1H, s, H-11), 6.78 (1H, d, J = 4.4 Hz, H-1), 6.35 (1H, s, H-5), 5.39 (1H, d, J
= 4.4 Hz, H-2), 3.99 (3H, s, OCH3-6), 2.50, 2.20, 1.90, 1.70 (each 2H, m, camphanoyl-
CH2), 1.56, 1.47 (each 3H, s, CH3-3,3), 1.12, 1.11, 1.05, 1.02, 0.98, 0.95 (each 3H, s,
camphanoyl-CH3); [α]D -30.0° (c = 0.0012, CHCl3); HRMS for (M+ + Na): calcd m/z
750.2527, found: 750.2523.
6.1.7.19. 1R,2R-(-)-Dicamphanoyl-3,3-dimethyl-6-methoxy-9-cyano-1,2-
dihydropyrano[2,3-c]xanthen-7(1H)-one (29): 65% Yield (starting from 30 mg of 37);
white solid; mp 165-167 °C; 1H NMR δ 8.59 (1H, s, H-8), 7.84 (1H, d, J = 8.8 Hz, H-10),
7.37 (1H, d, J = 8.8 Hz, H-11), 6.84 (1H, d, J = 4.8 Hz, H-1), 6.39 (1H, s, H-5), 5.40 (1H, d,
J = 4.8 Hz, H-2), 4.02 (3H, s, OCH3-6), 2.50, 2.10, 1.90, 1.70 (each 2H, m, camphanoyl-
CH2), 1.54, 1.50 (each 3H, s, CH3-3,3), 1.14, 1.12, 1.05, 1.00, 0.93, 0.92 (each 3H, s,
camphanoyl-CH3); [α]D –51.0° (c = 0.0023, CH2Cl2); HRMS for (M+ + Na): calcd m/z
750.2527, found: 750.2526.
6.1.8. 1R,2R-(-)-Dicamphanoyl-3,3-dimethyl-6-methoxy-1,2-dihydropyrano[2,3-
c]xanthen-7(1H)-one oxime (8)—Compound 7 (32 mg, 0.045 mmol) and NH2OH HCl
(5 mg, 0.07 mmol) were dissolved in anhydrous pyridine (1 mL) and stirred at 100 °C,
monitored by TLC. At completion, the reaction mixture was poured into water and extracted
with EtOAc. The organic layer was collected and the crude product was purified by PTLC
with hexane:EtOAc = 1:1 to yield 8 as a white solid. 80% yield; mp 160-162 °C; 1H NMR δ
8.99 (1H, d, J = 8.4 Hz, H-8), 7.41 (1H, t, J = 7.2, 8.4 Hz, H-10), 7.21 (1H, t, J = 7.2, 8.4
Hz, H-9), 7.15 (1H, d, J = 8.4 Hz, H-11), 6.76 (1H, d, J = 4.8 Hz, H-1), 6.33 (1H, s, H-5),
5.35 (1H, d, J = 4.8 Hz, H-2), 3.98 (3H, s, OCH3-6), 2.50, 2.20, 1.90, 1.70 (each 2H, m,
camphanoyl-CH2), 1.52, 1.45 (each 3H, s, CH3-3,3), 1.13, 1.12, 1.03, 0.99, 0.91, 0.89 (each
3H, s, camphanoyl-CH3); [α]D –141.3° (c = 0.0023, CH2Cl2); HRMS for (M+ + Na): calcd
m/z 740.2683, found: 740.2714.
6.1.9. 1R,2R-(-)-Dicamphanoyl-3,3-dimethyl-6-hydroxy-1,2-dihydropyrano[2,3-
c]xanthen-7(1H)-one (9)—Compound 7 (20 mg, 0.028 mmoL) was heated with 48%
HBr (2.0 mL) at reflux temperature for 12 h. The reaction mixture was allowed to cool,
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diluted with water, and filtered and then the residue was washed thoroughly with water. The
crude product was purified by PTLC with hexane:EtOAc = 1:1 to yield 9 as a white solid.
63% yield; mp 165-167 °C; 1H NMR δ 13.67 (1H, s, OH-6), 8.25 (1H, d, J = 7.2 Hz, H-8),
7.74 (1H, d, J = 8.8, 8.4 Hz, H-10), 7.46 (1H, d, J = 8.4 Hz, H-11), 7.41 (1H, d, J = 8.8, 7.2
Hz, H-10), 6.63 (1H, d, J = 4.8 Hz, H-1), 6.44 (1H, s, H-5), 5.36 (1H, d, J = 4.8 Hz, H-2),
2.50, 2.20, 1.90, 1.70 (each 2H, m, camphanoyl CH2), 1.50, 1.47 (each 3H, s, CH3-3,3),
1.17, 1.11, 1.08, 1.07, 0.98, 0.97 (each 3H, s, camphanoyl CH3); [α]D –70.0° (c = 0.0023,
CH2Cl2); HRMS for (M+ + NH4): calcd m/z 706.2864, found: 706.2896.
6.1.10. 1R,2R-(-)-Dicamphanoyl-3,3-dimethyl-5-bromo-6-methoxy-1,2-
dihydropyrano[2,3-c]xanthen-7(1H)-one (25)—A mixture of 7 (50 mg, 0.071 mmoL),
NBS (17.0 mg, 0.10 mmol) and CH2Cl2 (2 mL) was heated to 100 °C for 2 h under high-
absorption microwave conditions. At completion, the mixture was concentrated and purified
by PTLC with hexane:EtOAc = 3:2 to afford pure 25 as a white solid (43.7 mg). 78.9%
yield; mp 139-140 °C; 1H NMR δ 8.29 (1H, d, J = 8.0 Hz. H-8), 7.65 (1H, t, J = 7.6, 7.6 Hz,
H-10), 7.39 (1H, t, J = 8.0, 7.6 Hz, H-9), 7.29 (1H, d, J = 7.6 Hz, H-11), 6.90 (1H, d, J = 4.8
Hz, H-1), 5.44 (1H, d, J = 4.8 Hz, H-2), 4.05 (3H, s, OCH3-6), 2.53, 2.21, 1.95, 1.75 (each
2H, m, camphanoyl CH2), 1.14, 1.13, 1.05, 1.01, 0.94, 0.93 (each 3H, s, camphanoyl CH3);
[α]D -51.3° (c = 0.0023, CHCl3); HRMS for (M+ + Na): calcd m/z 803.1679, found:
803.1680.
6.1.11. 1R,2R-(-)-Dicamphanoyl-3,3,9-trimethyl-5-bromo-6-methoxy-1,2-
dihydropyrano[2,3-c]xanthen-7(1H)-one (26)—The procedure was identical to that
used for the preparation of 25. 56% yield (starting from 50 mg of 12); white solid; mp
170-171 °C; 1H NMR δ 8.06 (1H, s, H-8), 7.45 (1H, d, J = 8.4 Hz, H-10), 7.19 (1H, d, J =
8.4 Hz, H-11), 6.88 (1H, d, J = 4.4 Hz, H-1), 5.43 (1H, d, J = 4.4 Hz, H-2), 4.04 (3H, s,
OCH3-6), 2.44 (3H, s, CH3-9), 2.50, 2.20, 1.90, 1.70 (each 2H, m, camphanoyl CH2), 1.58,
1.58 (each 3H, s, CH3-3,3), 1.41, 1.13, 1.04, 1.01, 0.93, 0.91 (each 3H, s, camphanoyl CH3);
[α]D -10.8° (c = 0.0078, CHCl3); HRMS for (M+ + Na): calcd m/z 817.1836, found:
817.1826.
6.1.12. 1R,2R-(-)-Dicamphanoyl-3,3-dimethyl-6-hydroxy-9-bromomethyl-1,2-
dihydropyrano[2,3-c]xanthen-7(1H)-one (27)—A mixture of 12 (50 mg, 0.07 mmoL),
NBS (18.6 mg, 0.105 mmoL), and 3-chloroperbenzoic acid (2 mg, 0.01 mmoL), dissolved in
1 mL of anhydrous CCl4 was heated to 100 °C for 5 h under high-absorption microwave
conditions. At completion, the mixture was concentrated and the residue was purified by
PTLC with hexane:EtOAc = 1:1 to afford pure 27 (31.3 mg, white solid). 56.1% yield; 1H
NMR δ 13.62 (1H, s, OH-6), 8.20 (1H, d, J = 2.0 Hz, H-8), 7.74 (1H, dd, J = 8.8, 2.0 Hz,
H-10), 7.48 (1H, d, J = 8.8 Hz, H-11), 6.89 (1H, s, H-5), 5.30, 5.30 (each 1H, s, H-1,2), 2.44
(2H, s, CH2Br-9), 2.40, 2.15, 1.90, 1.70 (each 2H, m, camphanoyl CH2), 1.56, 1.55 (each
3H, s, CH3-3,3), 1.11, 1.10, 1.04, 1.03, 0.98, 0.85 (each 3H, s, camphanoyl CH3); HRMS for
(M+ + Na): calcd m/z 817.1836, found: 817.1822.
6.2. HIV-1 infectivity assay
Anti-HIV-1 activity was measured as reduction in Luc reporter gene expression after a
single round of virus infection of TZM-bl cells. HIV-1 at 200 TCID50 and various dilutions
of test samples (eight dilutions, four-fold stepwise) were mixed in a total volume of 100 μL
growth medium in 96-well black solid plates (Corning-Costar). After 48-h incubation,
culture medium was removed from each well and 100 μL of Bright Glo luciferase reagent
was added to each culture well. The luciferase activity in the assay wells was measured
using a Victor 2 luminometer. The 50% inhibitory dose (IC50) was defined as the sample
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concentration that caused a 50% reduction in Relative Luminescence Units (RLU) compared
to virus control wells after subtraction of background RLU.
6.3. Cytotoxic activity assay
The general procedure was performed according to CytoTox-Glo™ cytotoxic activity assay
instructions for using product G9290, G9291 and G9292. (Promega)
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Structures of DCP (1–3) and DCK (4–5) analogs.
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Structures of novel DCX analogs.
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Synthesis of compounds 34a-q. Reagents and conditions: (i) Eaton's reagent, reflux; (ii) 4,4-
dimethoxy-2-methyl-2-butanol, pyridine, microwave, 220 °C/4h; (iii) MeI, K2CO3, acetone,
reflux.
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Synthesis of compounds 6, 7, 10–24. Reagents and conditions. (i) K3Fe(CN)6, (DHQ)2PYR,
K2OsO2(OH)4, K2CO3, methanesulfonamide, t-butanol/H2O, 0 °C; (ii) (S)-camphanoyl
chloride, DMAP, CH2Cl2, rt.
Zhou et al. Page 21














Synthesis of compounds 8 and 9. Reagents and conditions: (i) NH2OH·HCl, pyridine, reflux;
(ii) HBr/CH3COOH, reflux.
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Synthesis of compounds 25–27. Reagents and conditions: (i) NBS, CH2Cl2, microwave 100
°C/2h; (ii) mCPBA, NBS, CCl4, reflux.
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Synthesis of compounds 28 and 29. Reagents and conditions: (i) Zn(CN)2, tetrakis
(triphenylphosphine)palladium(0), DMF, 160 °C; (ii) K3Fe(CN)6, K2CO3, (DHQ)2PYR,
K2OsO2(OH)4, methanesulfonamide, t-butanol/H2O, 0 °C; (iii) (S)-camphanoyl chloride,
DMAP, CH2Cl2, rt.
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Table 2
Anti-HIV activity of DCX analogs against drug-resistant RTMDR1 HIV strain.a
Compound CC50 (μM) EC50
b (μM) SIc
6 >29.8 0.546 >54.6
7 >14.3 0.074 >193.2
11 >14.0 0.363 >38.6
12 11.4 0.081 140.7
13 11.6 0.37 31.4
16 10.8 0.42 25.7
21 26.0 0.16 162.5
22 >13.9 0.065 >213.8
2 12.1 0.11 110
a
All data presented in this table were averaged from at least three independent experiments.
b
This assay was performed in TZM-bl cell infected with HIVRTMDR1 strain.
c
Selectivity index = CC50 ÷ EC50.
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